Acid Sphingomyelinase Deficiency (ASMD) Market is segmented By Therapy (XENPOZYME (olipudase alfa), Other Enzyme Replacement Therapies (ERT)), By Geog....
Market Size in USD
CAGR12.1%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 12.1% |
Market Concentration | High |
Major Players | Sanofi, Orphazyme, Takeda Pharmaceutical, Actelion Pharmaceuticals |
The acid sphingomyelinase deficiency (ASMD) market is estimated to be valued at USD 134.6 Mn in 2024 and is expected to reach USD 300 Mn by 2031, growing at a compound annual growth rate (CAGR) of 12.1% from 2024 to 2031. The market is expected to showcase significant growth during the forecast period due to the rising diagnosis of ASMD and growing access to enzyme replacement therapies.